Company Overview
About Catena Biosciences
Catena Biosciences is a United States-based biotechnology company — backed by Y Combinator (W21) with $9.1 million in total funding including a $2.35 million seed round in May 2024 from LongeVC, CA Innovation Fund, Civilization Ventures, Pioneer Fund, Freeflow Ventures, Caffeinated Capital, and BrightEdge Capital, plus NIH SBIR grants — developing next-generation protein conjugation technology that enables the rapid, selective attachment of functional payloads (drugs, labels, polymers, other proteins) to therapeutic proteins using natural amino acids as conjugation handles, generating $750,000 in annual revenue as of June 2025 and serving pharmaceutical companies and researchers developing antibody-drug conjugates (ADCs), bispecific antibodies, vaccine adjuvants, and next-generation protein therapeutics for autoimmune disorders, oncology, and infectious disease.
Business Model & Competitive Advantage
Catena Biosciences' Multi Payload Conjugate (MPC) platform addresses a fundamental limitation in antibody-drug conjugate development: conventional protein conjugation methods (NHS ester chemistry, maleimide chemistry) attach drug payloads to antibodies at non-specific sites (random lysine or cysteine residues throughout the antibody) — creating heterogeneous conjugates with variable drug-to-antibody ratios (DAR) that affect pharmacokinetics, efficacy, and safety. The FDA-approved ADC Kadcyla (ado-trastuzumab emtansine) exemplifies the heterogeneity problem: different antibody molecules in the same batch carry 0, 2, 4, or 8 drug molecules, creating a mixture with variable potency and off-target toxicity. Catena's site-specific conjugation chemistry (using engineered unnatural amino acid handles or novel selective chemistry at specific natural amino acid sites) enables pharmaceutical researchers to produce homogeneous conjugates with defined, controlled conjugation sites and stoichiometries — improving the ADC therapeutic window and manufacturing consistency critical for clinical development.
Competitive Landscape 2025–2026
In 2025, Catena Biosciences competes in the protein conjugation technology, ADC development tools, and biologics manufacturing services market with Ajinomoto (ADC site-specific conjugation services), Innate Pharma (site-specific conjugation technology platform, acquired by AstraZeneca), and Abzena (ADC CDMO with conjugation services, $150M raised) for pharmaceutical company ADC and protein therapeutic conjugation service adoption. The ADC market has become one of oncology's hottest drug development categories — 14 FDA-approved ADCs by 2025 and 100+ in clinical development — creating growing demand for conjugation services and technology licenses that improve ADC development efficiency. NIH SBIR grant funding validates Catena's scientific approach and provides non-dilutive capital for platform development. Caffeinated Capital's biotech investment focus and Amgen's participation reflect therapeutic protein development industry validation. The 2025 strategy focuses on growing the ADC development service revenue from oncology biotech clients, licensing the MPC platform to large pharmaceutical companies for internal ADC programs, and building the GMP-compatible conjugation manufacturing for clinical-stage ADC customers.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Catena Biosciences is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Not So Random Others
Yoneda Labs
Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit
Decoda Health
Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Grap
Fortuna Health
Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowi
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
AbbVie
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp
Compare Catena Biosciences with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Catena Biosciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Catena Biosciences Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Catena Biosciences vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →